title: Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma.
abstract: Serum prostate secretory protein (PSP) levels were measured in 49 patients with benign prostatic hyperplasia (BPH), 144 patients with various stages of prostatic carcinoma (CaP), and 82 CaP patients who were followed serially. PSP values were compared with serum levels of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP). In the BPH group, PSP was elevated (> 10 ng/ml) in 41% of patients, whereas PSA (> 4 ng/ml) and PAP (> 3.3 ng/ml) were elevated in 39% and 23% of the cases, respectively. PSP levels were elevated in 48% of the CaP pretreatment specimens, compared to 79% for PSA and 40% for PAP. PSP levels in cancer patients who had intracapsular disease were about two to three times higher than those observed for PAP. PSP was found to be the only marker elevated in eight (6%) pretreatment CaP patient serum specimens, while PAP was never found to be elevated when PSA was normal. PSP serum concentrations correlated with the clinical course of the disease in 79% of patients, compared with 90% for PSA and 66% for PAP. In certain patients, monitored over time, disease correlation was reflected in serum values with only a single biomarker, i.e., 1% with PAP, 8% with PSP, and 10% with PSA. This study has shown that PSP is a less sensitive serum biomarker than PSA, but more sensitive than PAP for detection and monitoring the early stages of prostate cancer. This suggests that PSP as a biomarker may be a useful adjunct for the management of a subpopulation of low-stage and -grade CaP.
authors.affiliation: Department of Microbiology, Eastern Virginia Medical School, Norfolk 23501.
authors.forename: C L
authors.initials: CL
authors.lastname: Huang
authors.forename: D
authors.initials: D
authors.lastname: Brassil
authors.forename: M
authors.initials: M
authors.lastname: Rozzell
authors.forename: P F
authors.initials: PF
authors.lastname: Schellhammer
authors.forename: G L
authors.initials: GL
authors.lastname: Wright
mesh_terms: D000135:Acid Phosphatase / Q000097:blood*; D015415:Biomarkers / Q000097:blood*; D002352:Carrier Proteins / Q000097:blood*; D006801:Humans; D008297:Male; D011237:Predictive Value of Tests; D011467:Prostate / Q000378:metabolism; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis; D029584:Prostatic Secretory Proteins; D012680:Sensitivity and Specificity
chemical_list: D015415:Biomarkers; D002352:Carrier Proteins; D029584:Prostatic Secretory Proteins; C028321:estramustine-binding protein; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen